Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

17.03.2022 - Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year ...

Related Keywords

Houston ,Texas ,United States ,Neda Safarzadeh ,Peterl Hoang ,Katharine Knobil ,Company Board Of Directors ,Marker Therapeutics Inc ,Drug Administration ,Nasdaq ,Chief Executive ,Myeloid Leukemia ,Company Sponsored Phase ,Investigational New Drug ,Clinical Programs ,Orphan Drug ,Marker Therapeutics ,Private Securities Litigation Reform Act ,Consolidated Statements ,Operating Activities ,Investing Activities ,Financing Activities ,Investor Relations ,